课题基金 / 基金详情

'EPSRC and SFI Centre for Doctoral Training in Engineered Tissues for Discovery, Industry and Medicine

'EPSRC and SFI Centre for Doctoral Training in Engineered Tissues for Discovery, Industry and Medicine
EPSRC 和 SFI 发现、工业和医学工程组织博士培训中心
批准号:
EP/S02347X/1
负责人:
金额:
$927.06万
依托单位:
依托单位国家:
英国
项目类别:
Training Grant
财政年份:
2019
资助国家:
英国
项目状态:
未结题
起止时间:
2019 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
终身CDT将专注于非动物技术(NAT)的开发,用于药物开发、毒理学和再生医学。工业生命科学部门占所有商业研发支出的22%,在英国创造了640亿GB的营业额,预计未来十年将以10%的年增长率增长。来自多个来源的分析[1,2]强调了技能短缺对该行业造成的限制,特别是在工程和物理科学领域。我们成功地吸引了实收合作伙伴投资于技能培训,以NAT的形式提供下一代药物开发、毒理学和再生医学(高级治疗药物产品,ATMP)解决方案,这表明英国在这一增长领域的需求。CDT是及时的,因为它不仅是需要发展的科学,而且是整个NAT生态系统--科学、制造、监管、政策和通信。因此,需要CDT模式来培养一个由熟练领域领导者组成的互联社区,以促进英国该行业的经济增长。我们的利益相关者合作伙伴和行业俱乐部已同意帮助我们提供实现目标所需的培训。他们的意愿再次表明了我们在该领域对毕业生的需求。CDT的培训将涉及优先领域7--“生物经济工程”的方方面面。具体地说,我们将:(1)提供与行业合作开发并与行业相关的培训。-我们通过与来自生物材料、细胞制造、合同研究组织和制药部门的行业合作伙伴合作,满足该行业的需求。(2)促进多学科工程和物理科学培训,使学生能够利用新出现的机会。-我们通过具有生物工程、细胞工程、芯片技术、物理、电子工程、组学技术、生命科学、临床科学、再生医学和制造业等背景的监督员队伍,建立了多学科能力;这一群体将分享这种多学科能力。每个学生都将有一门物理科学、一门生物医学和一位利益相关者主管,这再次加强了多学科的能力。(3)应对与药品制造相关的关键挑战。-我们将通过制药公司和活跃在药物筛选中的CRO(包括阿斯特拉捷利康、Charles River实验室、赛普乐、LGC、日产化学、Reproell、Sygnature Discovery和天津)的利益相关者参与来应对药物制造挑战。(4)嵌入创造性的方法来扩大产品规模和过程开发。-我们将通过与包括过程创新中心、细胞和基因治疗启动器在内的合作伙伴以及将NAT推向市场的工业合作伙伴(如Cytochroma)密切合作,嵌入这些方法。InSphero和OxSyBio。(5)确保学生了解负责任的研究和创新(RRI)、数据问题、卫生经济学、监管问题和用户参与战略。-为了确保学生了解RRI、数据问题、经济学、监管问题和用户参与战略,我们与企业家商学院一起开展了专业技能培训,以教授经济学和企业家精神,利用RRI的领域,链接到NC3R、SNBTS和MHRA,以帮助监管培训和利益相关者合作伙伴的整体参与,以帮助用户参与。由Pharma、UKRI和行业编制的统计数据,加上我们的利益相关者愿意参与CDT,充分证明了该行业对高技能毕业生的需求。我们的培训是专门为这些毕业生量身定做的,并建立一个包容的、有凝聚力的社区,拥有良好的科学、专业和RRI技能。[1]https://goo.gl/qNMTTD[2]https://goo.gl/J9u9eQ
英文摘要
The lifETIME CDT will focus on the development of non-animal technologies (NATs) for use in drug development, toxicology and regenerative medicine.The industrial life sciences sector accounts for 22% of all business R&D spend and generates £64B turnover within the UK with growth expected at 10% pa over the next decade. Analysis from multiple sources [1,2] have highlighted the limitations imposed on the sector by skills shortages, particularly in the engineering and physical sciences area.Our success in attracting pay-in partners to invest in training of the skills to deliver next-generation drug development, toxicology and regenerative medicine (advanced therapeutic medicine product, ATMP) solutions in the form of NATs demonstrates UK need in this growth area. The CDT is timely as it is not just the science that needs to be developed, but the whole NAT ecosystem - science, manufacture, regulation, policy and communication. Thus, the CDT model of producing a connected community of skilled field leaders is required to facilitate UK economic growth in the sector.Our stakeholder partners and industry club have agreed to help us deliver the training needed to achieve our goals. Their willingness, again, demonstrates the need for our graduates in the sector. This CDT's training will address all aspects of priority area 7 - 'Engineering for the Bioeconomy'. Specifically, we will: (1) Deliver training that is developed in collaboration with and is relevant to industry. - We align to the needs of the sector by working with our industrial partners from the biomaterials, cell manufacture, contract research organisation and Pharma sectors.(2) Facilitate multidisciplinary engineering and physical sciences training to enable students to exploit the emerging opportunities.- We build in multidisciplinarity through our supervisor pool who have backgrounds ranging from bioengineering, cell engineering, on-chip technology, physics, electronic engineering, -omic technologies, life sciences, clinical sciences, regenerative medicine and manufacturing; the cohort community will share this multidisciplinarity. Each student will have a physical science, a biomedical science and a stakeholder supervisor, again reinforcing multidisciplinarity.(3) Address key challenges associated with medicines manufacturing.- We will address medicines manufacturing challenges through stakeholder involvement from Pharma and CROs active in drug screening including Astra Zeneca, Charles River Laboratories, Cyprotex, LGC, Nissan Chemical, Reprocell, Sygnature Discovery and Tianjin.(4) Embed creative approaches to product scale-up and process development.- We will embed these approaches through close working with partners including the Centre for Process Innovation, the Cell and Gene Therapy Catapult and industrial partners delivering NATs to the marketplace e.g. Cytochroma, InSphero and OxSyBio.(5) Ensure students develop an understanding of responsible research and innovation (RRI), data issues, health economics, regulatory issues, and user-engagement strategies.- To ensure students develop an understanding of RRI, data issues, economics, regulatory issues and user-engagement strategies we have developed our professional skills training with the Entrepreneur Business School to deliver economics and entrepreneurship, use of TERRAIN for RRI, links to NC3Rs, SNBTS and MHRA to help with regulation training and involvement of the stakeholder partners as a whole to help with user-engagement.The statistics produced by Pharma, UKRI and industry, along with our stakeholder willingness to engage with the CDT provides ample proof of need in the sector for highly skilled graduates. Our training has been tailored to deliver these graduates and build an inclusive, cohesive community with well-developed science, professional and RRI skills.[1] https://goo.gl/qNMTTD[2] https://goo.gl/J9u9eQ
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
SRSF3抑制剂SFI003逆转急性髓系白血病耐药性的功能与机制研究
  • 批准号:
    2026JJ60275
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    邢程
  • 依托单位:
致病疫霉RxLR效应蛋白SFI7抑制马铃薯ETI免疫反应的分子机制研究
  • 批准号:
    31800134
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2018
  • 负责人:
    王洪洋
  • 依托单位:
马铃薯致病疫霉RXLR效应蛋白SFI5在抑制番茄MTI早期反应中分子机制的研究
  • 批准号:
    31701862
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    25.0万元
  • 批准年份:
    2017
  • 负责人:
    郑祥梓
  • 依托单位:
黔北农村留守学龄儿童意外伤害特征及SFI干预模式研究
  • 批准号:
    81160350
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2011
  • 负责人:
    石修权
  • 依托单位: